Pharma’s AI prospects get nudged into the future with EU’s AI act
The EU Artificial Intelligence (AI) Act may protect citizens, but some experts in the life sciences industry are worried about…
All articles by Akosua Mireku
Akosua Mireku
@AkosuaMireku1
Akosua Mireku is a healthcare reporter for Pharmaceutical Technology. Akosua has a Bsc in medical physiology from the University of Manchester. She is particularly interested in topics in neuroscience, rare diseases, and global health equality
-
-
Myostatin inhibitors target muscle loss prevention to fill gap in GLP-1RA market
As weight loss drugs boom in popularity, some companies are focusing their sights on therapies for muscle loss prevention, a…
-
UK life sciences venture capital funding lags behind
In 2024, life sciences was the only tech sector analysed where the UK had not improved its global share of…
-
EU Health Data Space strikes a chord in EU harmonisation plans
Amidst a wave of regulatory changes in the European Union (EU) that are underway, the new EU Health Data Space…
-
Inborn errors of metabolism elicit unique challenges for therapy development
In recent years, major progress has been made in the development of gene therapies for rare diseases. However, research for…
-
EU reshapes HTAs: is the industry ready for it?
Amid a wave of healthcare regulatory changes in the EU, an update on health technology assessment (HTA) regulation is set…
-
Neumora shares sink following Phase III flop in MDD
Neumora Therapeutics saw a drop of more than 80% in its share price following the announcement of a Phase III…
-
Flu vaccine strategy on the line as new US leaders anticipated to take charge
As countries in the Northern hemisphere deal with the flu season, experts say regulation surrounding flu vaccines could be due…
-
PrEP therapies offer new hope in HIV preventive landscape as vaccine failures amass
Research activity in the human immunodeficiency viruses space (HIV) is pivoting towards pre-exposure prophylaxis (PrEP) therapies as vaccine failures rack…
-
How to adapt to choppy waters in biotech ecosystem
As the US enters a new political era, experts predict that the pharmaceutical and clinical trials industry will have to…